Ameriprise
FBRX icon

Ameriprise’s Forte Biosciences FBRX Stock Holding History

Ameriprise’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.9M Sell
111,788
-41,239
-27% -$1.19M ﹤0.01% 2776
2025
Q4 		$4.17M Buy
153,027
+83,135
+119% +$1.46M ﹤0.01% 2567
2025
Q3 		$1.05M Buy
+69,892
New +$805K ﹤0.01% 3340

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Ameriprise's FBRX Position: Q1 2026 in Review

Ameriprise reduced its Forte Biosciences (FBRX) stake by 27% in Q1 2026, selling an estimated $1.19M and leaving 111,788 shares worth $2.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2776.

Ameriprise first reported a position in FBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.17M in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Ameriprise held 111,788 shares of Forte Biosciences worth $2.9M as of Q1 2026.
  • Ameriprise sold 41,239 Forte Biosciences shares in Q1 2026, an estimated $1.19M.
  • Forte Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2776 holding.
  • Ameriprise first reported a position in Forte Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Ameriprise's Forte Biosciences position peaked at $4.17M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.